Planet Briefing

First published · Last updated

P3.18.09 SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy

A journal article reports a Phase 3 clinical trial evaluating Olomorasib plus immunotherapy for patients with stage II–III KRAS G12C–mutant non–small cell lung cancer after definitive therapy. The source is published by Elsevier BV (journal article).

Comparison of over survival and hazard ratios (HR) in clinical trials incorporating immunotherapy in the first line for patients with non-small cell lung cancer. The treatment arms without and with immunotherapy are compared in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189, KEYNOTE-407, CHECKMATE-227, CHECKMATE 9LA, IMpower110, IMpower130, and IMpower150.Nasser NJ, Gorenberg M, Agbarya A.Pharmaceuticals 2020, 13(11), 373; https://doi.org/10.3390/ph13110373
Illustrative image: Comparison of over survival and hazard ratios (HR) in clinical trials incorporating immunotherapy in the first line for patients with non-small cell lung cancer. The treatment arms without and with immunotherapy are compared in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189, KEYNOTE-407, CHECKMATE-227, CHECKMATE 9LA, IMpower110, IMpower130, and IMpower150.Nasser NJ, Gorenberg M, Agbarya A.Pharmaceuticals 2020, 13(11), 373; https://doi.org/10.3390/ph13110373 — Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373 https://doi.org/10.3390/ph13110373/Wikimedia Commons, CC BY 4.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
6/10
Geographic reach
1/10
Global importance
3/10
Impact magnitude
4/10
Positivity
6/10
Urgency
2/10

Why it matters

The study addresses treatment in a genetically defined subgroup of NSCLC patients.

Sources

Report an issue